

RECEIVED  
NOV 2 1999  
TECH CENTER 1600/2900

IN THE CLAIMS:

Cancel claim 22.

Amend claims 15, 16 and 21 as follows:

15. (Twice amended) A method for improving inhibition of gastric acid secretion comprising administering to a patient in need thereof the oral pharmaceutical formulation as claimed in any of claims 7-10 or 21.

16. (Twice amended) A method for improving the treatment of gastrointestinal disorders associated with excess acid secretion comprising administering to a patient in need thereof the oral pharmaceutical formulation as claimed in any of claims 7-10 or 21.

In claim 21, delete "or 19".

Add new claims 23-25

23. The oral pharmaceutical formulation according to claim 19, wherein the  $\text{H}^+$ ,  $\text{K}^+$ -ATPase inhibitor is a compound of the formula I




wherein



Het<sub>1</sub> is

*C3*  
*Conn*


Het<sub>2</sub> is




or




or



X =



or



wherein

N in the benzimidazole moiety means that one of the ring carbon atoms substituted by R<sub>6</sub>-R<sub>9</sub> optionally may be exchanged for a nitrogen atom without any substituents;

R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, fluorine-substituted alkoxy, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

R<sub>4</sub> and R<sub>5</sub> are the same or different and selected from the group consisting of hydrogen, alkyl and aralkyl;